U.S. RESEARCH ROUNDUP-Avidity Biosciences, Broadcom, Cara Therapeutics

Enovis

13/06/2024 08:24

June 13 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed
companies, including Avidity Biosciences, Broadcom and Cara Therapeutics, on Thursday. 
    
    HIGHLIGHTS
                 * Avidity Biosciences Inc  RNA.O : Leerink Partners raises target price to $56 from $38
 
                 * Broadcom Inc  AVGO.O : TD Cowen raises target price to $1,750 from $1,500    
 
                 * Cara Therapeutics Inc  CARA.O : Canaccord Genuity cuts to hold from buy    
 
        
Following is a summary of research actions on U.S. companies reported by Reuters on Thursday. Stock entries are in
alphabetical order. 

                 * Amphenol  APH.N : Evercore ISI adjusts PT to $75 from $150 to reflect 2-for-1 stock split
 
                 * Avidity Biosciences Inc  RNA.O : Evercore ISI raises target price to $45 from $40
 
                 * Avidity Biosciences Inc  RNA.O : Leerink Partners raises target price to $56 from $38
 
                 * Avidity Biosciences Inc  RNA.O : Needham raises target price to $46 from $35
 
                 * Avidity Biosciences Inc  RNA.O : Raymond James raises target price to $90 from $66
 
                 * Broadcom Inc  AVGO.O : Evercore ISI raises target price to $2010 from $1620
 
                 * Broadcom Inc  AVGO.O : TD Cowen raises target price to $1,750 from $1,500
 
                 * Cara Therapeutics Inc  CARA.O : Canaccord Genuity cuts to hold from buy
 
                 * Caseys General Stores Inc  CASY.O : Jefferies raises target price to $445 from $342
 
                 * Celsius Holdings Inc  CELH.O : TD Cowen cuts target price to $85 from $95
 
                 * Charles River Laboratories International Inc  CRL.N : Baird raises PT to $271 from $270
 
                 * Corning Inc  GLW.N : Jefferies raises target price to $33.5 from $30
 
                 * Enovis Corp  ENOV.N : JP Morgan initiates coverage with neutral rating; price target $53
 
                 * Lexeo Therapeutics Inc  LXEO.O : Baird initiates coverage with outperform rating; PT $28
 
                 * Meritage Homes Corp  MTH.N : Evercore ISI raises target price to $219 from $217
 
                 * Twist Bioscience Corp  TWST.O : TD Cowen raises target price to $65 from $55
 
                 * Williams Companies Inc  WMB.N : RBC raises target price to $44 from $40
 
        

 (Compiled by Bengaluru Newsroom)
 ((Diaries@thomsonreuters.com))